Experts Hope Mesothelioma Patients to Be Treated With A New Approach
Malignant mesothelioma patients always needed a new treatment approach from the beginning. And so, researchers devised a new line of treatment known as immunotherapy. But during the course of time, this technique could not prove as effective as the experts thought.
The technique called immunotherapy was devised for extended survival of malignant mesothelioma patients. But its continuous use ended up making such patients sicker. However, the case was not so initially as the patients are known to have initially derived benefits from its use.
Looking into the above, a team of
researchers in the UK (United Kingdom) are known to have explored combining the
ongoing treatment with a new experimental drug.
With this line of treatment, experts
in the UK hope that this new treatment will support the effectiveness of
Mesothelioma Patients May Get Benefit with New Treatment
Until now, immunotherapy worked quite
well against the malignant mesothelioma which falls under a rare type of
Ever since experts started using the
combination of nivolumab (Opdivo) and ipilimumab (Yervoy) later that same year,
it started benefiting mesothelioma patients.
It all happened in June 2020 when FDA
had approved the use of the drug called Keytruda. And since then loads of
patients suffering from one or other type of mesothelioma have been able to get
But over the passage of time, it was
found that he new approach slowly declined the effectiveness as the treatment
relied to immune system to target and kill cancer cells.
When such a finding came, the team of
researchers from the Institute of Cancer Research in the United Kingdom tried
to devise a new line of treatment to extend the lives of such patients.
In the new approach, oncologists
started exploring to combine the immunotherapy drugs with a new medication
called guadecitabine so as to overcome the risk of resistance.
Immunotherapy Combination Gives Positive Results to Mesothelioma Patients
Patients who are diagnosed with
mesothelioma are well informed that it is a rare type of cancer which is often
fatal. Still, experts continue to find new innovations to handle such a menace.
The recent study conducted in the UK
didn't actually include mesothelioma patients. They simply included all those
patients diagnosed with different types of cancers and are even treated with
the same drugs as the asbestos-related cancer.
As per a report, after such patients received the guadecitabine/pembrolizumab combination, as many as one third patients found their cancer halted in one way or the other.